Weekly Recap: Q3 estimates missed and Spencer Stiles named next CEO

What happened

Stryker reported third-quarter sales of $6.52 billion, up 7.7%, and adjusted earnings per share of $3.52, up 10.3%; both were below estimates. The company cut its 2026 guidance, bought back $1 billion in shares and named Spencer Stiles as its next CEO, succeeding Kevin Lobo.

Confirmed

Global impact / market context

Missing estimates and lowering 2026 guidance may point to weaker expected growth, which can weigh on revenue expectations and investor views of Stryker’s shares. The $1 billion repurchase returns cash to shareholders, while a new CEO could change priorities for spending and business strategy.

Analyst inference

Stryker is also changing how it manages orthopaedics and expanding surgical offerings through an investment and U.S. sales rights for CMR Surgical’s robot, plus its completed ZuriMED acquisition. These moves may affect future product sales and costs, but the article gives no financial contribution estimates.

Analyst inference

What to watch

1. Watch whether future results show sales and adjusted earnings recovering from the third-quarter shortfall, and whether Stryker changes the reduced 2026 guidance again. Analyst inference
2. Watch for details on Spencer Stiles’s priorities as incoming CEO, including whether the leadership change alters business organization, product investment or plans for spending. Analyst inference
3. Track the U.S. launch performance of CMR Surgical’s Versius robot: the article says Stryker may acquire CMR depending on that platform’s success. Confirmed

Evidence

• Original source link unavailable